Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

We previously reported on GSK’s lawsuit filed in April of this year against Pfizer, Pharmacia & Upjohn, and BioNTech, alleging infringement of five mRNA patents, including three patents now ...

According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

PHILADELPHIA, Nov. 6, 2024 /PRNewswire/ -- Legal-Bay LLC, the premier Pre Settlement Funding Company, reports that the ongoing legal disputes against UK Pharmaceutical company GlaxoSmithKline (GSK ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...